How can the personal discovery process evolve personalized medicine? An interview with Laura Towart.
Clicks: 482
ID: 44845
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
67.2
/100
482 views
324 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #1 of 3 articles by views in personalized medicine
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Laura is the Founder and CEO of My Personal Therapeutics, a London-based digital health company offering the most advanced personalized cancer therapeutics. She is also the Founder and former CEO of Celmatix, a leader in diagnostics and predictive analytics for female infertility and women's health. She is a graduate of the Weill Cornell Graduate School of Medical Sciences and Memorial Sloan Kettering Cancer Center's Doctoral program and received a Certificate in Bioinformatics. She holds a BS/BA in Biology/English from The George Washington University. Besides being passionate about personalized medicine, she enjoys exploring the world with her children Julian, Valentina and Delphine.
| Reference Key |
a-towart2019howpersonalized
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | A Towart, Laura; |
| Journal | personalized medicine |
| Year | 2019 |
| DOI |
10.2217/pme-2019-0087
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.